230 related articles for article (PubMed ID: 14616411)
1. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.
Purkins L; Wood N; Ghahramani P; Love ER; Eve MD; Fielding A
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):37-44. PubMed ID: 14616412
[TBL] [Abstract][Full Text] [Related]
3. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
Purkins L; Wood N; Kleinermans D; Love ER
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
[TBL] [Abstract][Full Text] [Related]
4. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
5. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):51-5. PubMed ID: 14616414
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
7. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
Muirhead GJ; Faulkner S; Harness JA; Taubel J
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
[TBL] [Abstract][Full Text] [Related]
8. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.
Purkins L; Wood N; Kleinermans D; Greenhalgh K; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):17-23. PubMed ID: 14616409
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole does not affect the steady-state pharmacokinetics of digoxin.
Purkins L; Wood N; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):45-50. PubMed ID: 14616413
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
17. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Dowell JA; Schranz J; Baruch A; Foster G
J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]